knowledge -WSS

knowledge

author：knowledge 2025-09-28 23:11:39 - browse：9517

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA weighs limits of animal data in assessing artificial wombs

focus

WSS

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

What happened to the House vote on health price transparency?

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Reanimated hearts work just as well for transplants, study finds

Senate bill would ban some hospital facility fees

Altering the blood type of lungs raises potential for universal organs for transplants

focus

knowledge

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

How the messy conversation about Dolly changed bioethics

How one medical school became remarkably diverse

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Virginia high school admissions case could be legal follow

Why the drug industry's warnings on the IRA's impact fall short

Hollywood unions extend contract negotiations for actors

Assistant physicians can help address the primary care shortage

In age of alternative facts, a scholarly course on calling out crap

Millions may soon lose Medicaid when they don't have to

explore

White House Covid adviser calls on docs to combat misinformation

Patients, doctors are clashing about side effects of hormonal birth control

People with substance use disorder deserve online privacy

Why the quest to eradicate polio has stumbled

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Eli Lilly CEO gives to Mike Pence presidential super PAC

leisure time

focus

focus

focus